Bristol-Myers Squibb Company PFD CONV 2 BMYMP OTC

Other OTC • Healthcare • Drug Manufacturers - General • US • USD

SharesGrow Score

45/100

0/7 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) reported total assets of $90.04B and total liabilities of $71.53B for fiscal year 2025, resulting in total equity of $18.51B.

The company held $10.67B in cash and short-term investments. Total debt stood at $47.14B, with net debt of $36.93B. The Debt-to-Equity (D/E) ratio was 2.55 (leveraged).

Current ratio is 1.26, suggesting adequate short-term liquidity. Interest coverage is 8.4x (strong).

Criteria supported by this page:

HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (51/100) — Total assets $90.04B and equity $18.51B support the company's competitive scale
VALUE (15/100) — Debt-to-Equity 2.55 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 45/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

45/100

SG Score

View full scorecard →

✗

VALUE

15/100

Price-to-Earnings & upside

→ Valuation

FUTURE

40/100

Analyst consensus

→ Forecast

PAST

75/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

51/100

→ Income

✗

GROWTH

30/100

→ Income

INCOME

55/100

→ Income

Bristol-Myers Squibb Company PFD CONV 2 Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$90.04B	$92.6B	$95.16B	$96.82B
Total Liabilities	$71.53B	$76.22B	$65.67B	$65.7B
Total Debt	$47.14B	$51.2B	$41.46B	$40.72B
Cash & Investments	$10.67B	$10.86B	$12.28B	$9.12B
Total Stockholders Equity	$18.47B	$16.34B	$29.43B	$31.06B